Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Conditions:   Advanced Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Melanoma of Unknown Primary;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologi c Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Unresectable Acral Lentiginous Melanoma;   Unresectable Melanoma;   Unresectable Mucosal Melanoma Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Patient Observation;   Biological: Pembrolizumab Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI) Not yet recruiting

Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials